Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Nimotuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nimotuzumab (h-R3,[2] BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-377-1mg 1mg 3090
GMP-Bios-ab-377-10mg 10mg 21890
GMP-Bios-ab-377-100mg 100mg 148000
GMP-Bios-ab-377-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Nimotuzumab biosimilar,Whole mAb)
INN Name Nimotuzumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI Structure3gkw:HL
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesBiocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience
Conditions ApprovedAnaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer
Conditions ActiveCervical cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer
Conditions DiscontinuedGastric cancer;Polycystic kidney disease;Prostrate cancer;Brain metastases;Squamous cell cancer
Development Techna